Pharmaceuticals

Obesity Rise Driving Growth In Peptide-Based Metabolic Disorders Therapeutics Is Supporting Development Across The Peptide Based Metabolic Disorders Therapeutics Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Market Value Of The Peptide Based Metabolic Disorders Therapeutics Market Projected To Expand During 2026–2030?

The peptide based metabolic disorders therapeutics market has observed substantial expansion in recent years. Its value is expected to rise from $34.1 billion in 2025 to $39.05 billion in 2026, progressing at a compound annual growth rate (CAGR) of 14.5%. This historical growth can be attributed to several factors including the increasing prevalence of type 2 diabetes, the early success of liraglutide and exenatide therapies, the growing clinical validation of peptide drugs, rising obesity rates in developed economies, and an improved understanding of metabolic pathways.

The peptide based metabolic disorders therapeutics market is projected to experience swift expansion in the coming years. By 2030, this market is anticipated to reach $63.7 billion, demonstrating a compound annual growth rate (CAGR) of 13.0%. This projected growth is driven by factors such as the increasing global prevalence of obesity, the rising uptake of semaglutide and advanced peptides, greater investment in drug pipelines for metabolic disorders, a growing need for enduring weight management options, and innovations in peptide drug delivery methods. Key trends expected over the forecast period encompass a surge in the use of GLP-1 receptor agonist therapies, a heightened emphasis on managing obesity with peptide-based solutions, the wider availability of long-acting injectable peptide formulations, an increase in combination peptide treatments, and an escalating demand for metabolic treatments that are convenient for patients.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp

Which Significant Factors Are Encouraging Growth In The Peptide Based Metabolic Disorders Therapeutics Market?

The increasing incidence of obesity is anticipated to drive the expansion of the peptide-based metabolic disorders therapeutic market in the future. Obesity, a medical state defined by the accumulation of excessive body fat, presents significant health dangers. The growing number of obesity cases stems from inactive lifestyles, poor eating habits, genetic factors, and environmental conditions that encourage high-calorie food consumption and a lack of physical activity. Peptide-based treatments for metabolic disorders, including obesity, work by utilizing peptides to modulate metabolic processes, enhance insulin responsiveness, and regulate appetite. This ultimately leads to better patient health results and minimizes the long-term health complications linked to these persistent conditions. For example, data from December 2024, provided by the Office for Health Improvement and Disparities, a UK government body, indicated that the percentage of women with obesity in early pregnancy rose from 25.4% between 2022 and 2023 to 26.2% between 2023 and 2024. Consequently, the growing occurrence of obesity is fueling the peptide-based metabolic disorder therapeutics market.

Which Segment Divisions Form The Structure Of The Peptide Based Metabolic Disorders Therapeutics Market?

The peptide based metabolic disorders therapeutics market covered in this report is segmented –

1) By Drug Type: Liraglutide, Exenatide, Other Drug Type

2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity

2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide

3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders

What Trends Are Influencing The Peptide Based Metabolic Disorders Therapeutics Market?

Leading companies in the peptide-based metabolic disorders therapeutics market are actively developing innovative peptide-based treatments, such as anti-diabetic biosimilars, to address unfulfilled medical needs and expand available patient treatment options. Peptide-based anti-diabetic biosimilars are therapeutic drugs engineered to emulate existing peptide-based therapies for diabetes, offering similar efficacy and safety profiles to established medications, potentially lowering treatment costs through competitive pricing strategies. For instance, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Lirafit in India, a biosimilar version of the popular anti-diabetic drug Liraglutide. This product belongs to the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This category of drugs mimics the action of the naturally occurring GLP-1 hormone, which is vital in regulating blood sugar levels. Clinical trials for this biosimilar have demonstrated its effectiveness in lowering glycemic parameters, promoting weight reduction, and enhancing cardiovascular safety. These constitute crucial benefits for managing diabetes and associated conditions like obesity and cardiovascular diseases.

Who Are The Key Market Participants In The Peptide Based Metabolic Disorders Therapeutics Market?

Major companies operating in the peptide based metabolic disorders therapeutics market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Ipsen S.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Amgen Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Amarin Corporation plc

Access The Complete Peptide Based Metabolic Disorders Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report

What Is The Largest Regional Market In The Peptide Based Metabolic Disorders Therapeutics Market?

North America was the largest region in the peptide based metabolic disorders therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Peptide Based Metabolic Disorders Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp

Browse Through More Reports Similar to the Global Peptide Based Metabolic Disorders Therapeutics Market 2026, By The Business Research Company

Peptide Based Metabolic Disorders Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Metabolic Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795